Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECODE-CKD
2021-000995-13Phase 2Active
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing Dapagliflozin arm with Placebo arm (2 arms). Primary endpoint: Change in LV mass index. Started Jan 2022; status: active.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2021-000995-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000995-13.